Publications by authors named "Zev A Wainberg"

Claim this Profile
D
Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.
Yelena Y Janjigian, Do-Youn Oh, Meredith Pelster, Zev A Wainberg, Subhransu Prusty

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results.
Zev A Wainberg, Colin D Weekes, Muhammad Furqan, Pashtoon M Kasi, Craig E Devoe

Nat Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma.
Elizabeth C Smyth, Kyoung-Mee Kim, Sun Young Rha, Zev A Wainberg, Hayden Honeycutt

Cancer Treat Rev· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.
Kohei Shitara, Sylvie Lorenzen, Jin Li, Yuxian Bai, Manuel González Fernández, Zev A Wainberg

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
Yelena Y Janjigian, Salah-Eddin Al-Batran, Zev A Wainberg, Kei Muro, Daniela Molena

N Engl J Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.
Shen Zhao, Ying Cheng, Qiming Wang, Xingya Li, Jun Liao, Zev A Wainberg

Nat Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies.
Quchang Ouyang, Jordi Rodon, Yan Liang, Xinhong Wu, Qun Li, Zev A Wainberg

J Hematol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE).
Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, Dan G Duda, Robin Park, Zev A Wainberg

Future Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Jaffer A Ajani, Thomas A D'Amico, David J Bentrem, Carlos U Corvera, Prajnan Das, Zev A Wainberg

J Natl Compr Canc Netw· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial.
Sun Young Rha, Yanqiao Zhang, Anneli Elme, Roberto Pazo Cid, Ahmet Alacacioglu, Zev A Wainberg

JCO Precis Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies.
Yelena Y Janjigian, Michael Cecchini, Kohei Shitara, Peter C Enzinger, Zev A Wainberg

JCO Precis Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3).
Zev A Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R Chandana

Future Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies.
Yelena Y Janjigian, Michael Cecchini, Kohei Shitara, Peter C Enzinger, Zev A Wainberg

JCO Precis Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.
Vincent Ribrag, Lara Iglesias, Filippo De Braud, Brigette Ma, Tomoya Yokota, Zev A Wainberg

Eur J Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.
Samuel J Klempner, Mohamad Bassam Sonbol, Zev A Wainberg, Hope Elizabeth Uronis, Vi K Chiu

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial.
Sun Young Rha, Yanqiao Zhang, Anneli Elme, Roberto Pazo Cid, Ahmet Alacacioglu, Zev A Wainberg

JCO Precis Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3.
Zev A Wainberg, Eileen M O'Reilly

Nat Rev Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.
Erkut H Borazanci, Nathan Bahary, Vincent Chung, Timothy K Huyck, Ebenezer A Kio, Zev A Wainberg

Oncologist· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WRN Helicase: Is There More to MSI-H than Immunotherapy?
Zev A Wainberg

Cancer Discov· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option.
Haeseong Park, Samuel J Klempner, Joseph Chao, Zev A Wainberg, Mariusz Lukanowski

Front Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma.
Jacob E Till, Lee McDaniel, Changgee Chang, Qi Long, Shannon M Pfeiffer, Zev A Wainberg

Nat Commun· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoclonal antibodies that target fibroblast growth factor receptor 2 isoform b and Claudin-18 isoform 2 splicing variants in gastric cancer and other solid tumours.
Masuko Katoh, Izuma Nakayama, Zev A Wainberg, Kohei Shitara, Masaru Katoh

Clin Transl Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Zev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, Shukui Qin, Kensei Yamaguchi

Gastric Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.
Masuko Katoh, Yohann Loriot, Giovanni Brandi, Simona Tavolari, Zev A Wainberg

Nat Rev Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer.
Faithlore P Gardner, Zev A Wainberg, Christos Fountzilas, Nathan Bahary, Mark S Womack

Cancers (Basel)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis